5 research outputs found
The NF1 somatic mutational landscape in sporadic human cancers
Abstract Background Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour predisposition syndrome. Heritable constitutional mutations in the NF1 gene result in dysregulation of the RAS/MAPK pathway and are causative of NF1. The major known function of the NF1 gene product neurofibromin is to downregulate RAS. NF1 exhibits variable clinical expression and is characterized by benign cutaneous lesions including neurofibromas and café-au-lait macules, as well as a predisposition to various types of malignancy, such as breast cancer and leukaemia. However, acquired somatic mutations in NF1 are also found in a wide variety of malignant neoplasms that are not associated with NF1. Main body Capitalizing upon the availability of next-generation sequencing data from cancer genomes and exomes, we review current knowledge of somatic NF1 mutations in a wide variety of tumours occurring at a number of different sites: breast, colorectum, urothelium, lung, ovary, skin, brain and neuroendocrine tissues, as well as leukaemias, in an attempt to understand their broader role and significance, and with a view ultimately to exploiting this in a diagnostic and therapeutic context. Conclusion As neurofibromin activity is a key to regulating the RAS/MAPK pathway, NF1 mutations are important in the acquisition of drug resistance, to BRAF, EGFR inhibitors, tamoxifen and retinoic acid in melanoma, lung and breast cancers and neuroblastoma. Other curiosities are observed, such as a high rate of somatic NF1 mutation in cutaneous melanoma, lung cancer, ovarian carcinoma and glioblastoma which are not usually associated with neurofibromatosis type 1. Somatic NF1 mutations may be critical drivers in multiple cancers. The mutational landscape of somatic NF1 mutations should provide novel insights into our understanding of the pathophysiology of cancer. The identification of high frequency of somatic NF1 mutations in sporadic tumours indicates that neurofibromin is likely to play a critical role in development, far beyond that evident in the tumour predisposition syndrome NF1
Rapid and reversible knockdown of endogenously tagged endosomal proteins via an optimized HaloPROTAC degrader
Inducing
post-translational protein knockdown is an important approach
to probe biology and validate drug targets. An efficient strategy
to achieve this involves expression of a protein of interest fused
to an exogenous tag, allowing tag-directed chemical degraders to mediate
protein ubiquitylation and proteasomal degradation. Here, we combine
improved HaloPROTAC degrader probes with CRISPR/Cas9 genome editing
technology to trigger rapid degradation of endogenous target proteins.
Our optimized probe, HaloPROTAC-E, a chloroalkane conjugate of high-affinity
VHL binder VH298, induced reversible degradation of two endosomally
localized proteins, SGK3 and VPS34, with a DC<sub>50</sub> of 3–10
nM. HaloPROTAC-E induced rapid (∼50% degradation after 30 min)
and complete (<i>D</i><sub>max</sub> of ∼95% at 48
h) depletion of Halo-tagged SGK3, blocking downstream phosphorylation
of the SGK3 substrate NDRG1. HaloPROTAC-E more potently induced greater
steady state degradation of Halo tagged endogenous VPS34 than the
previously reported HaloPROTAC3 compound. Quantitative global proteomics
revealed that HaloPROTAC-E is remarkably selective inducing only degradation
of the Halo tagged endogenous VPS34 complex (VPS34, VPS15, Beclin1,
and ATG14) and no other proteins were significantly degraded. This
study exemplifies the combination of HaloPROTACs with CRISPR/Cas9
endogenous protein tagging as a useful method to induce rapid and
reversible degradation of endogenous proteins to interrogate their
function